Testosterone Gel

Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for testosterone gel 1.62 percent and that it has notified AbbVie Inc., the owner of the Reference Listed Drug of its filing.
Perrigo Confirms FDA Approval For Testosterone Gel 1%Perrigo Company (Nasdaq: PRGO) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application for testosterone gel 1%. Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel 1%.
Perrigo Confirms Filing For Testosterone Gel And Patent Infringement LawsuitAllegan's Perrigo confirms a regulatory finding for generic testosterone gel and a lawsuit by the company that makes the patented version.

More From CBS Detroit

Daily J
Valenti and Foster

Watch & Listen